U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filling a continued processurion application (CPA) under 37 C.F.R. § 1.514(PTC)SR29) instead of a RCE to be eligible for the application from addistringer provisions of the AIPA.

NEQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL

DECLIECT

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

on of information unless it dis	plays a valid OMB control number.
Application Number	10/763,165
Filing Date	January 26, 2004
First Named Inventor	Daisuke Ishizuka
Group Art Unit	2625
Examiner Name	Tran, Douglas Q.
Attorney Docket Number	03560.003429

	See (Ma	Change r. 20, 20	es to A 100), 1	pplication Examination and Provisional Application Practic 233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which establi	ce, Final Rule, 65 Fe shed RCE practice.	ed. Reg. 50092 (Aug. 16, 2000)); Interim Rule, 65 Fed. Reg. 14865			
1.	Su	bmiss	sion required under 37 C.F.R. § 1.114							
	a.	Х	Pre	viously submitted						
	i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on May 22, 2008 (Any unentered amendment(s) referred to above will be entered).									
		ii. iii.		Consider the arguments in the Appeal Brie Other:						
	b.	\mathbf{x}	End	losed						
		i. ii. iii. iv.		Preliminary Amendment Affidavit(s)/Declaration(s) Information Disclosure Statement (IDS) Other:						
2.	Mis	scellar	neou	3						
a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103®) for a period of										
		months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)								
	b.	ш	Other:							
3.	Fe	The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.								
	a.	X		Director is hereby authorized to charge any	deficiencies in	the following fees, or cr	redit any overpayments, to			
Daposit Account No06-1205 i RCE fee required under 37 C.F.R. § 1.17(e) ii Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)										
	b.			requisite fee in the amount of \$810.00 to co	ver the RCE fil	ing fee is being paid ele	ctronically.			
	C.	브	Pay	ment by credit card (Form PTO-2038 enclosed)				_		
				SIGNATURE OF APPLICANT, A	TTORNEY	, OR AGENT REC	QUIRED	Ī		
Name (Print/Type))	Donald H. Heckenberg, Jr.		ation No. ey/Agent)	60,081	Ī			
Signature			/Donald H. Heckenberg, Jr./	Date	October 22, 200	October 22, 2008				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the manut of time you are required to complete his form should be sent to the Cell information (Titler, U.S. Patient and Trademark (Office, Washington, DC 20231. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patients & Den CEL Washington, DC 20231.